Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
118 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Anaplastic Astrocytoma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma - Pipeline Review, H2 2016, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape. Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed and usually involves surgery and radiation therapy, with chemotherapy during or following radiation. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Astrocytoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 3, 7 and 7 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 2 molecules, respectively.Anaplastic Astrocytoma. Anaplastic Astrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Anaplastic Astrocytoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Anaplastic Astrocytoma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Anaplastic Astrocytoma Overview 8 Therapeutics Development 9 Pipeline Products for Anaplastic Astrocytoma - Overview 9 Pipeline Products for Anaplastic Astrocytoma - Comparative Analysis 10 Anaplastic Astrocytoma - Therapeutics under Development by Companies 11 Anaplastic Astrocytoma - Therapeutics under Investigation by Universities/Institutes 12 Anaplastic Astrocytoma - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Anaplastic Astrocytoma - Products under Development by Companies 15 Anaplastic Astrocytoma - Products under Investigation by Universities/Institutes 16 Anaplastic Astrocytoma - Companies Involved in Therapeutics Development 17 AngioChem Inc. 17 Astellas Pharma Inc. 18 Axelar AB 19 Boehringer Ingelheim GmbH 20 Burzynski Research Institute, Inc. 21 Cavion LLC 22 Celldex Therapeutics, Inc. 23 Millennium Pharmaceuticals Inc 24 Novartis AG 25 Orbus Therapeutics, Inc. 26 Pfizer Inc. 27 Tocagen Inc. 28 TVAX Biomedical, Inc. 29 Anaplastic Astrocytoma - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Combination Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 afatinib dimaleate - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 alisertib - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Antineoplaston Therapy - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 AXL-1717 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 bendamustine hydrochloride - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 CDX-1401 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Cellular Immunotherapy for Gliomas - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Cellular Immunotherapy for Oncology - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 DNX-2401 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 eflornithine hydrochloride - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 flucytosine + TBio-01 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 flucytosine ER + vocimagene amiretrorepvec - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 irinotecan hydrochloride + TBio-02 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 M-032 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 mibefradil dihydrochloride - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 nilotinib - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 p28 - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 paclitaxel trevatide - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 palbociclib - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 TVI-Brain-1 - Drug Profile 112 Product Description 112 Mechanism Of Action 112 R&D Progress 112 Anaplastic Astrocytoma - Dormant Projects 113 Anaplastic Astrocytoma - Discontinued Products 114 Anaplastic Astrocytoma - Product Development Milestones 115 Featured News & Press Releases 115 Sep 26, 2016: Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer 115 Dec 07, 2015: Burzynski Research Institute Announces Favorable Objective Response Rates and Overall Survival in Adults with Anaplastic Astrocytoma Following Antineoplastons A-10 and AS2-1 115 Jun 18, 2015: Burzynski Research Institute Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma 116 Appendix 117 Methodology 117 Coverage 117 Secondary Research 117 Primary Research 117 Expert Panel Validation 117 Contact Us 117 Disclaimer 118
List of Tables Number of Products under Development for Anaplastic Astrocytoma, H2 2016 9 Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Anaplastic Astrocytoma - Pipeline by AngioChem Inc., H2 2016 17 Anaplastic Astrocytoma - Pipeline by Astellas Pharma Inc., H2 2016 18 Anaplastic Astrocytoma - Pipeline by Axelar AB, H2 2016 19 Anaplastic Astrocytoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 20 Anaplastic Astrocytoma - Pipeline by Burzynski Research Institute, Inc., H2 2016 21 Anaplastic Astrocytoma - Pipeline by Cavion LLC, H2 2016 22 Anaplastic Astrocytoma - Pipeline by Celldex Therapeutics, Inc., H2 2016 23 Anaplastic Astrocytoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 24 Anaplastic Astrocytoma - Pipeline by Novartis AG, H2 2016 25 Anaplastic Astrocytoma - Pipeline by Orbus Therapeutics, Inc., H2 2016 26 Anaplastic Astrocytoma - Pipeline by Pfizer Inc., H2 2016 27 Anaplastic Astrocytoma - Pipeline by Tocagen Inc., H2 2016 28 Anaplastic Astrocytoma - Pipeline by TVAX Biomedical, Inc., H2 2016 29 Assessment by Monotherapy Products, H2 2016 30 Assessment by Combination Products, H2 2016 31 Number of Products by Stage and Target, H2 2016 33 Number of Products by Stage and Mechanism of Action, H2 2016 35 Number of Products by Stage and Route of Administration, H2 2016 37 Number of Products by Stage and Molecule Type, H2 2016 39 Anaplastic Astrocytoma - Dormant Projects, H2 2016 113 Anaplastic Astrocytoma - Discontinued Products, H2 2016 114
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
